

Nirav R. Shah, M.D., M.P.H. Commissioner Sue Kelly Executive Deputy Commissioner

Update: Medicaid Fee- for- Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

Effective March 13, 2014, the following changes will be made to the Dispense Brand Name Drug when Less Expensive than Generic Program:

- Epivir HBV and Myfortic will be added to the program.
- Adderall immediate release (IR), Singulair granules and Temodar will be removed from the program.

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

IMPORTANT BILLING INFORMATION

Prescription claims submitted to the Medicaid program **do not require** the submission of Dispense As Written/Product Selection Code of '1'; **Pharmacies can submit any valid NCPDP field (408-D8) value.**

List of Brand Name Drugs included in this program* (Updated 3/03/14):

Accolate	Felbatol	Solaraze
Adderall XR	Focalin XR(15mg,30mg,45mg)	Soriatane
Alphagan P 0.15%	Gabitril 2mg, 4mg	Symbyax
Astelin	Hepsera	Tegretol suspension
Bactroban cream	Kadian	Tegretol XR
Carbatrol	Lidoderm	TOBI
Catapres-TTS	Lovenox	Tobradex
Combivir	Marinol	Toprol XL
Depakote sprinkle	Myfortic	Tricor
Dovonex cream	Niaspan	Trileptal suspension
Diastat	Prandin	Trilipix
Diovan HCT	Prevpac	Trizivir
Duetact	Prograf	Vancocin
Epivir	Pulmicort Respules	Valtrex
Epivir HBV	Sanctura XR	Ziagen tablet

^{*}List is subject to change

Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs, promoting the use of the most cost-effective product.